Devyser Diagnostics AB (publ) (STO:DVYSR)

Market Cap	1.27B -35.7%
Revenue (ttm)	250.50M +15.5%
Net Income	-8.40M
EPS	-0.51
Shares Out	16.66M
PE Ratio	n/a
Forward PE	30.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,866
Average Volume	24,601
Open	76.10
Previous Close	76.00
Day's Range	76.10 - 78.10
52-Week Range	74.00 - 159.60
Beta	0.61
RSI	29.84
Earnings Date	Mar 25, 2026

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analys...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 116
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2025, Devyser Diagnostics AB's revenue was 250.50 million, an increase of 15.49% compared to the previous year's 216.90 million. Losses were -8.40 million, -86.34% less than in 2024.